ArticleJournal of virology2001
Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines.
Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00073216 (A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Clade B Gag DNA/PLG and Env DNA/PLG Microparticles Vaccine and a Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant Vaccine in Healthy, HIV-1 Uninfected Adult Participants), which is not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Clade B Gag DNA/PLG and Env DNA/PLG Microparticles Vaccine and a Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant Vaccine in Healthy, HIV-1 Uninfected Adult Participants
Who cites it
38 citing papers in PubMed, 178 citations in OpenAlex.
- Immunogenicity and protective efficacy of virosome based vaccines against Newcastle disease.Tropical animal health and production · 2010Trial
- Nano toolbox in immune modulation and nanovaccines.Trends in biotechnology · 2022Review
- Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.Drug delivery and translational research · 2020Review
- The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection.Viruses · 2020Review
- Polylactide-Based Reactive Micelles as a Robust Platform for mRNA Delivery.Pharmaceutical research · 2020Article
- Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation.Nanotheranostics · 2017Review
- Nanocarriers for DNA Vaccines: Co-Delivery of TLR-9 and NLR-2 Ligands Leads to Synergistic Enhancement of Proinflammatory Cytokine Release.Nanomaterials (Basel, Switzerland) · 2015Article
- Nanostructures for the Inhibition of Viral Infections.Molecules (Basel, Switzerland) · 2015Review
- Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.Journal of materials chemistry. B · 2014Article
- Attenuated Salmonella typhimurium delivering DNA vaccine encoding duck enteritis virus UL24 induced systemic and mucosal immune responses and conferred good protection against challenge.Veterinary research · 2012Article
- Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
- Technologies for enhanced efficacy of DNA vaccines.Expert review of vaccines · 2012Review
- Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccination.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.The Journal of infectious diseases · 2011Article
- Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses.Expert review of vaccines · 2010Review
- Prospects for control of emerging infectious diseases with plasmid DNA vaccines.Journal of immune based therapies and vaccines · 2009Article
- DNA/amphiphilic block copolymer nanospheres promote low-dose DNA vaccination.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Polymeric Materials for Gene Delivery and DNA Vaccination.Advanced materials (Deerfield Beach, Fla.) · 2009Article
- Enhanced immune response of DNA vaccine (VP1-pCDNA) adsorbed on cationic PLG for foot and mouth disease in guinea pigs.Virus genes · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
The effectiveness of cationic microparticles with adsorbed DNA at inducing immune responses was investigated in mice, guinea pigs, and rhesus macaques. Plasmid DNA vaccines encoding human immunodeficiency virus (HIV) Gag and Env adsorbed onto the surface of cationic poly(lactide-coglycolide) (PLG) microparticles were shown to be substantially more potent than corresponding naked DNA vaccines. In mice immunized with HIV gag DNA, adsorption onto PLG increased CD8(+) T-cell and antibody responses by approximately 100- and approximately 1,000-fold, respectively. In guinea pigs immunized with HIV env DNA adsorbed onto PLG, antibody responses showed a more rapid onset and achieved markedly higher enzyme-linked immunosorbent assay and neutralizing titers than in animals immunized with naked DNA. Further enhancement of antibody responses was observed in animals vaccinated with PLG/DNA microparticles formulated with aluminum phosphate. The magnitude of anti-Env antibody responses induced by PLG/DNA particles was equivalent to that induced by recombinant gp120 protein formulated with a strong adjuvant, MF-59. In guinea pigs immunized with a combination vaccine containing HIV env and HIV gag DNA plasmids on PLG microparticles, substantially superior antibody responses were induced against both components, as measured by onset, duration, and titer. Furthermore, PLG formulation overcame an apparent hyporesponsiveness of the env DNA component in the combination vaccine. Finally, preliminary data in rhesus macaques demonstrated a substantial enhancement of immune responses afforded by PLG/DNA. Therefore, formulation of DNA vaccines by adsorption onto PLG microparticles is a powerful means of increasing vaccine potency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.